Recruiting

REBECCA Real-world Early BrEast CanCer mAnagement

This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.

ClinicalTrials.gov IDNCT06856343

PhaseNot Applicable

Enrollment126

SponsorAstraZeneca

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Breast Cancer

About this study

This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.

Primary outcomes

Proportion of patients who receive Olaparib for the full treatment duration (18 months after inclusion)

Eligibility information

Inclusion Criteria: * Male or female aged ≥ 18 years * Patient diagnosed with HER2-negative eBC * Patient about to be initiated with adjuvant Olaparib at their physician's discretion * Patient has been informed and does not object to participation in the study. Exclusion Criteria: * Patient not consenting to participate. * Patients included in the Early Access Program

Study locations

Research Site, Clermont-Ferrand, Auvergne-Rh ne-Alpes 63050 France
Research Site, Gleizé, Auvergne-Rh ne-Alpes 69400 France
Research Site, Grenoble, Auvergne-Rh ne-Alpes 38000 France
Research Site, Lyon, Auvergne-Rh ne-Alpes 69317 France
Research Site, Metz-Tessy, Auvergne-Rh ne-Alpes 74370 France
Research Site, Saint-Etienne, Auvergne-Rh ne-Alpes 42030 France
Research Site, Saint-Priest-en-Jarez, Auvergne-Rh ne-Alpes 42271 France
Research Site, Thonon-les-Bains, Auvergne-Rh ne-Alpes 74200 France
Research Site, Valence, Auvergne-Rh ne-Alpes 26000 France
Research Site, Valence, Auvergne-Rh ne-Alpes 26953 France

Showing 10 of 58 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.